{
    "id": 32223,
    "fullName": "FGFR2 - TTC28",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FGFR2-TTC28 results from the fusion of FGFR2 and TTC28 (Cancer Res 2019;79(13 Suppl):Abstract nr 2206). FGFR2-TTC28 has not been characterized and therefore, the effect on protein function is unknown (PubMed, Jan 2020).",
            "references": [
                {
                    "id": 16500,
                    "pubMedId": null,
                    "title": "Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2206"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2263,
        "geneSymbol": "FGFR2",
        "terms": [
            "FGFR2",
            "BBDS",
            "BEK",
            "BFR-1",
            "CD332",
            "CEK3",
            "CFD1",
            "ECT1",
            "JWS",
            "K-SAM",
            "KGFR",
            "TK14",
            "TK25"
        ]
    },
    "variant": "FGFR2 - TTC28",
    "createDate": "01/23/2020",
    "updateDate": "01/23/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 23331,
                "geneSymbol": "TTC28",
                "terms": [
                    "TTC28",
                    "TPRBK"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 19980,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Infigratinib (BGJ398) treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of cholangiocarcinoma harboring FGFR2-TTC28 fusion (Cancer Res 2019;79(13 Suppl):Abstract nr 2206).",
            "molecularProfile": {
                "id": 34738,
                "profileName": "FGFR2 - TTC28"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16500,
                    "pubMedId": null,
                    "title": "Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2206"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34738,
            "profileName": "FGFR2 - TTC28",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}